The quality of healthcare provided to women has never been more relevant. That’s why there’s Women’s Health 2024: Beyond the Annual Visit. Join us!
8:00 – 8:05 AM | Welcome, Introductions, Program Announcements Anita L. Nelson, MD, Barbara Dehn, WHNP-BC, and Amy Clouse, MD Program Co-Chairs |
8:05 – 8:40 AM | Breast Cancer Screening and Prevention for Average-Risk Patients Anita Nelson, MD
|
8:40 – 9:25 AM | New Hope Emerging in the Treatment of PTSD in Women Overcoming Suboptimal Outcomes Joseph F. Goldberg, MD & Roger McIntyre, MD |
9:25 – 10:00 AM | How Primary Care Practitioners Can Reduce Maternal Mortality and Morbidity in the US Anita Nelson, MD
|
10:00 – 10:15 AM | Question & Answer Session |
10:15 – 10:45 AM | Break |
10:45 – 11:20 AM | Barbara Dehn, WHNP-BC |
11:20 – 11:45 PM
| Importance of Early Diagnosis of Endometriosis: Patient and Clinical Considerations Lee Shulman, MD, Linda Bradley, MD, & James A. Simon, MD |
11:45 – 12:35 PM | Optimizing PPD Diagnosis and Treatment: The Role of Neuroactive Steroids and Multidisciplinary Care Kristina M. Deligiannidis, MD & Jennifer L. Payne, MD
|
12:35 – 1:15 PM | GLP-1 Receptor Agonists: Managing the Hype and the Hope Amy Clouse, MD |
1:15 – 1:35 PM | Question & Answer Session & Closing Remarks |
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Planning Committee:
Amy Clouse, MD
Associate Clinical Professor
Sidney Kimmel Medical College, Thomas Jefferson University
Associate Residency Director, Family Medicine Residency Program
Jefferson – Abington Health
Jenkintown, PA
Dr. Clouse has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Astellas
Barbara Dehn, WHNP-BC
Nurse Practitioner
Planned Parenthood
Albany, NY
Barbara Dehn has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Acella, Avion, Bonafide, Pharmavite, Shield Therapeutics
Vendor: Cord Blood Registry
Anita L. Nelson, MD
Professor and Chair of Obstetrics & Gynecology
Western University of Health Sciences, Pomona, CA
Professor Emeritus, Obstetrics & Gynecology, UCLA
Los Angeles, CA
Dr. Nelson has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Bayer, Exeltis USA, Inc, Merck, Myovant, Sumitomo Pharma America, Inc
Contracted Research: Daré Bioscience,Mylan Pharmaceuticals, Organon & Co, Sebela Pharmaceuticals, Sumitomo Pharma America, Viatris Pharmaceuticals, Inc
Faculty:
Linda Bradley, MD
Professor of Obstetrics & Gynecology and
Reproductive Medicine
Cleveland Clinic
Cleveland, OH
Dr. Bradley has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Receives Royalties: Wolters Kluwer, UpToDate
Medical Director: AAGL
Kristina Deligiannidis, MD
Director, Women’s Behavioral Health
Zucker Hillside Hospital, Northwell Health
New York, NY
Dr. Deligiannidis has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Premier Healthcare, Sage Therapeutics, Woebot Health
Consulting Fees: Biogen, Brii Biosciences, G H Research Ireland, Gerbera Therapeutics, Next Sense, Reunion Neuroscience
Joseph F. Goldberg, MD
Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Goldberg has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Receives royalties: American Psychiatric Publishing, Cambridge University Press
Consulting Fees: Genomind, Intra-Cellular Therapies, Luye Pharmaceuticals, Neumora, Neurelis, Otsuka, Sage Pharmaceuticals, Sunovion, Supernus
Speakers' bureau: AbbVie, Alkermes, Axsome, Bristol Myers Squibb
Roger McIntyre, MD
Professor of Psychiatry and Pharmacology
University of Toronto
Toronto, Canada
Dr. McIntyre has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: CIHR/GACD/National Natural Science Foundation of China (NSFC), and the Milken Institute
Consulting Fees: Abbvie, Alkermes, atai Life Sciences, Axsome, Bausch Health, Biogen, Boehringer Ingelheim, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris
CEO of Braxia Scientific Corp.
Jennifer L. Payne, MD
Professor and Vice Chair of Research
University of Virginia
Charlottesville, VA
Dr. Payne has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Janssen, Myriad
Ownership Interest: Dionysus Health
Consulting Fees: Biogen, Brii Biosciences, Flo Health, Sage Therapeutics
Lee Shulman, MD, FACOG, FACMG
The Anna Ross Lapham Professor and Chief
Division of Clinical Genetics
Feinberg School of Medicine
Northwestern University
Chicago, IL
Dr. Shulman has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alliance Pharma, Amazon, Juniper Genomics, Mayne, Shield
Speaker Fees: Daiichi Sankyo, Mayne, Shield
Other: Astellas (DSMB Chair)
James A. Simon, MD, CCD, NCMP, IF, FACOG
Clinical Professor, Obstetrics and Gynecology
George Washington University
Women’s Health & Research Consultants
IntimMedicine Specialists
Washington, DC
Dr. Simon has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Grant/research support: AbbVie, Inc., Bayer Healthcare LLC, Daré Bioscience, Ipsen, Mylan/Viatris Inc., Myovant Sciences, Sebela Pharmaceuticals Inc.
Consultant/advisory boards: Ascend Therapeutics, Bayer HealthCare Pharmaceuticals Inc., Besins Healthcare, Biote Medical, LLC, California Institute of Integral Studies (CIIS), Daré Bioscience, Femasys Inc., Khyria, Madorra Pty Ltd., Mayne Pharma, Inc., Pfizer Inc., Vella Bioscience Inc.
Speaker's bureaus: Ascend Therapeutics, Astellas Pharma, Inc., Mayne Pharma, Inc., Myovant Sciences, Inc., Pfizer Inc., Pharmavite LLC., Scynexis Inc.
Stockholder (direct purchase): Sermonix Pharmaceuticals
Reviewers/Content Planners/Authors:
This activity has been designed to meet the educational needs of ob-gyns and ob-gyn advanced practice nurses and physician assistants, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals who manage the health needs of women.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 5.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 5 contact hours/.5 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-103-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.
This activity is supported by independent educational grant(s) from Otsuka America Pharmaceutical Inc. and Sage Therapeutics, Inc.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
8:00 – 8:05 AM | Welcome, Introductions, Program Announcements Anita L. Nelson, MD, Barbara Dehn, WHNP-BC, and Amy Clouse, MD Program Co-Chairs |
8:05 – 8:40 AM | Breast Cancer Screening and Prevention for Average-Risk Patients Anita Nelson, MD
|
8:40 – 9:25 AM | New Hope Emerging in the Treatment of PTSD in Women Overcoming Suboptimal Outcomes Joseph F. Goldberg, MD & Roger McIntyre, MD |
9:25 – 10:00 AM | How Primary Care Practitioners Can Reduce Maternal Mortality and Morbidity in the US Anita Nelson, MD
|
10:00 – 10:15 AM | Question & Answer Session |
10:15 – 10:45 AM | Break |
10:45 – 11:20 AM | Barbara Dehn, WHNP-BC |
11:20 – 11:45 PM
| Importance of Early Diagnosis of Endometriosis: Patient and Clinical Considerations Lee Shulman, MD, Linda Bradley, MD, & James A. Simon, MD |
11:45 – 12:35 PM | Optimizing PPD Diagnosis and Treatment: The Role of Neuroactive Steroids and Multidisciplinary Care Kristina M. Deligiannidis, MD & Jennifer L. Payne, MD
|
12:35 – 1:15 PM | GLP-1 Receptor Agonists: Managing the Hype and the Hope Amy Clouse, MD |
1:15 – 1:35 PM | Question & Answer Session & Closing Remarks |
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Planning Committee:
Amy Clouse, MD
Associate Clinical Professor
Sidney Kimmel Medical College, Thomas Jefferson University
Associate Residency Director, Family Medicine Residency Program
Jefferson – Abington Health
Jenkintown, PA
Dr. Clouse has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Astellas
Barbara Dehn, WHNP-BC
Nurse Practitioner
Planned Parenthood
Albany, NY
Barbara Dehn has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Acella, Avion, Bonafide, Pharmavite, Shield Therapeutics
Vendor: Cord Blood Registry
Anita L. Nelson, MD
Professor and Chair of Obstetrics & Gynecology
Western University of Health Sciences, Pomona, CA
Professor Emeritus, Obstetrics & Gynecology, UCLA
Los Angeles, CA
Dr. Nelson has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Bayer, Exeltis USA, Inc, Merck, Myovant, Sumitomo Pharma America, Inc
Contracted Research: Daré Bioscience,Mylan Pharmaceuticals, Organon & Co, Sebela Pharmaceuticals, Sumitomo Pharma America, Viatris Pharmaceuticals, Inc
Faculty:
Linda Bradley, MD
Professor of Obstetrics & Gynecology and
Reproductive Medicine
Cleveland Clinic
Cleveland, OH
Dr. Bradley has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Receives Royalties: Wolters Kluwer, UpToDate
Medical Director: AAGL
Kristina Deligiannidis, MD
Director, Women’s Behavioral Health
Zucker Hillside Hospital, Northwell Health
New York, NY
Dr. Deligiannidis has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Premier Healthcare, Sage Therapeutics, Woebot Health
Consulting Fees: Biogen, Brii Biosciences, G H Research Ireland, Gerbera Therapeutics, Next Sense, Reunion Neuroscience
Joseph F. Goldberg, MD
Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Goldberg has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Receives royalties: American Psychiatric Publishing, Cambridge University Press
Consulting Fees: Genomind, Intra-Cellular Therapies, Luye Pharmaceuticals, Neumora, Neurelis, Otsuka, Sage Pharmaceuticals, Sunovion, Supernus
Speakers' bureau: AbbVie, Alkermes, Axsome, Bristol Myers Squibb
Roger McIntyre, MD
Professor of Psychiatry and Pharmacology
University of Toronto
Toronto, Canada
Dr. McIntyre has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: CIHR/GACD/National Natural Science Foundation of China (NSFC), and the Milken Institute
Consulting Fees: Abbvie, Alkermes, atai Life Sciences, Axsome, Bausch Health, Biogen, Boehringer Ingelheim, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris
CEO of Braxia Scientific Corp.
Jennifer L. Payne, MD
Professor and Vice Chair of Research
University of Virginia
Charlottesville, VA
Dr. Payne has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Janssen, Myriad
Ownership Interest: Dionysus Health
Consulting Fees: Biogen, Brii Biosciences, Flo Health, Sage Therapeutics
Lee Shulman, MD, FACOG, FACMG
The Anna Ross Lapham Professor and Chief
Division of Clinical Genetics
Feinberg School of Medicine
Northwestern University
Chicago, IL
Dr. Shulman has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alliance Pharma, Amazon, Juniper Genomics, Mayne, Shield
Speaker Fees: Daiichi Sankyo, Mayne, Shield
Other: Astellas (DSMB Chair)
James A. Simon, MD, CCD, NCMP, IF, FACOG
Clinical Professor, Obstetrics and Gynecology
George Washington University
Women’s Health & Research Consultants
IntimMedicine Specialists
Washington, DC
Dr. Simon has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Grant/research support: AbbVie, Inc., Bayer Healthcare LLC, Daré Bioscience, Ipsen, Mylan/Viatris Inc., Myovant Sciences, Sebela Pharmaceuticals Inc.
Consultant/advisory boards: Ascend Therapeutics, Bayer HealthCare Pharmaceuticals Inc., Besins Healthcare, Biote Medical, LLC, California Institute of Integral Studies (CIIS), Daré Bioscience, Femasys Inc., Khyria, Madorra Pty Ltd., Mayne Pharma, Inc., Pfizer Inc., Vella Bioscience Inc.
Speaker's bureaus: Ascend Therapeutics, Astellas Pharma, Inc., Mayne Pharma, Inc., Myovant Sciences, Inc., Pfizer Inc., Pharmavite LLC., Scynexis Inc.
Stockholder (direct purchase): Sermonix Pharmaceuticals
Reviewers/Content Planners/Authors:
This activity has been designed to meet the educational needs of ob-gyns and ob-gyn advanced practice nurses and physician assistants, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals who manage the health needs of women.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 5.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 5 contact hours/.5 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-103-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.
This activity is supported by independent educational grant(s) from Otsuka America Pharmaceutical Inc. and Sage Therapeutics, Inc.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
The Impact of Early Diagnosis in Improving Patient Outcomes in Endometriosis: Physical and Psychosocial Consequences
The Impact of Early Diagnosis in Improving Patient Outcomes in Endometriosis: Physical and Psychosocial Consequences
The Impact of Early Diagnosis in Improving Patient Outcomes in Endometriosis: Physical and Psychosocial Consequences
0.25 credits
Lee P. Shulman, MD, FACMG, FACOG
Sawsan As-Sanie, MD
Linda Bradley, MD
Patient-Centric Tools to Support Shared Decision-Making: Diagnosing and Assessing Endometriosis
Patient-Centric Tools to Support Shared Decision-Making: Diagnosing and Assessing Endometriosis
Patient-Centric Tools to Support Shared Decision-Making: Diagnosing and Assessing Endometriosis
0.25 creditsLee P. Shulman, MD, FACMG, FACOG
Linda Bradley, MD
Melissa Simon, MD
Pain Points: Weighing the Benefits and Drawbacks of the GnRH Antagonists Throughout the Endometriosis Treatment Journey
Pain Points: Weighing the Benefits and Drawbacks of the GnRH Antagonists Throughout the Endometriosis Treatment Journey
Pain Points: Weighing the Benefits and Drawbacks of the GnRH Antagonists Throughout the Endometriosis Treatment Journey
0.50 creditsLee P. Shulman, MD, FACMG, FACOG
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Sawsan As-Sanie, MD
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
1.75 program creditsLee P. Shulman, MD, FACMG, FACOG
Linda Bradley, MD
Samantha Denäe
We're glad to see you're enjoying Omnia Education…
but how about a more personalized experience?
